drugset

drugset / Trial / NCT00140452

Phase II Study Using Thalidomide for the Treatment of ALS

NCT00140452 ↗

Phase 2 Completed 24 enrolled Dartmouth-Hitchcock Medical Center Celgene Corporation · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The use of Thalidomide in patients with ALS who have disease progression.

Timeline

Start: 2005-02
Primary completion: —
Completion: 2007-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Thalidomide	Other / unclassified	400 mg	—

Indications